Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF-mutated Metastatic Melanoma”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Testing effectiveness (Phase 2)Study completedNCT02768207
What this trial is testing

Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Who this might be right for
Metastatic Melanoma
Hoffmann-La Roche 40
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Testing effectiveness (Phase 2)Study completedNCT02631447
What this trial is testing

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Who this might be right for
Metastatic Melanoma
Fondazione Melanoma Onlus 251
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Not applicableUnknownNCT05510466
What this trial is testing

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Who this might be right for
Metastatic Melanoma
University Hospital, Montpellier 18
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Not applicableStudy completedNCT05260684
What this trial is testing

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Who this might be right for
Melanoma
Pfizer 716
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10
Not applicableNo Longer AvailableNCT04489433
What this trial is testing

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals
Not applicableStudy completedNCT03663647
What this trial is testing

Advanced Melanoma in Russian Experience

Who this might be right for
Cutaneous Melanoma, Stage IVBRAF V600 Mutation
MelanomaPRO, Russia 382
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Early research (Phase 1)Ended earlyNCT01826448
What this trial is testing

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Who this might be right for
V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Daiichi Sankyo 13
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Early research (Phase 1)WithdrawnNCT02357732
What this trial is testing

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Who this might be right for
Metastatic Melanoma
University of Pittsburgh
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Not applicableStudy completedNCT06337617
What this trial is testing

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Who this might be right for
BRAF V600 Mutation Positive Melanoma
Novartis Pharmaceuticals 90
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Next Page